Fatigue News and Research

RSS

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Gut microbiome can play significant role in the body's response to gluten

Investigators interested in celiac disease, a chronic gastrointestinal disorder caused by an immunologic response to the ingestion of gluten, have wondered why only 2% to 5% of genetically susceptible individuals develop the disease.

8 Oct 2015

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Vertera Spine, a developer of medical devices with advanced functional surface technologies for spine applications, today announced it has received U.S. Food and Drug Administration 510(k) clearance for its COHERE Cervical Interbody Fusion Device.

6 Oct 2015

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Heart valve replacements made from tissue (bioprosthetic valves) have long been thought to be spared the complication of blood clot formation. Researchers have now found that about 15 percent of all bioprosthetic aortic heart valve patients develop blood clots on the leaflets affecting valve opening, regardless of whether the patient received the new valve via open-heart surgery or a minimally-invasive catheter procedure, a new study from the Cedars-Sinai Heart Institute shows.

6 Oct 2015

MS patients with history of neuro-ophthalmic syndromes perform poorly on visual neuropsychological testing

Scientists found that individuals with multiple sclerosis (MS) who had a history of neuro-ophthalmic syndromes performed poorly on visual neuropsychological tasks. The article, "Neuro-ophthalmic syndromes and processing speed in multiple sclerosis," was published in the Journal of Neuro-Ophthalmology.

6 Oct 2015

Backache awareness week starts 5th October

With BackCare Awareness Week reiterating the fact that 80 per cent of people, who work across all industries and professions, will suffer from back pain at some point in their lives, workplace equipment supplier Slingsby says that nearly all work related back pain can be avoided.

5 Oct 2015

Self-reported fatigue predicts myelodysplastic syndromes survival

Patient-reported fatigue severity is an independent prognostic marker for survival in patients with newly diagnosed intermediate-2- or high-risk myelodysplastic syndromes, according to research published in The Lancet Oncology.

1 Oct 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Combination of two targeted therapies increases survival in advanced melanoma

Latest results from a trial of a combination of two targeted therapies (dabrafenib and trametinib) to treat advanced melanoma have shown that patients are living significantly longer on the combined therapy than patients treated with another drug, vemurafenib, when used alone.

28 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

Kessler Foundation study may simplify cognitive assessment for MS in clinical settings

Kessler Foundation scientists found that the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) predicted performance of activities of daily living using Actual Reality (AR). The article, "Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and performance of everyday life tasks," was published in Multiple Sclerosis Journal.

25 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

22 Sep 2015

Endurance training affects how the brain and muscles communicate with each other

Using endurance training or strength and resistance training not only prepares an athlete for different types of sports, they can also change the way the brain and muscles communicate with each other.

21 Sep 2015

New report calls for greater focus to address quality of life issues in prostate cancer patients

A new report released today entitled Prostate Cancer: Living, not Just Surviving, which details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals, reveals that only 14 per cent of healthcare professionals feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems.

18 Sep 2015

Tolerability benefits with sunitinib schedule switch

Switching sunitinib treatment from a 4/2 to a modified 2/1 schedule can improve the tolerability profile for patients with metastatic renal cell carcinoma, say researchers.

17 Sep 2015

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study.

17 Sep 2015

Fatigue News and Research

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Gut microbiome can play significant role in the body's response to gluten

Vertera Spine receives FDA 510(k) clearance for COHERE Cervical Interbody Fusion Device

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

MS patients with history of neuro-ophthalmic syndromes perform poorly on visual neuropsychological testing

Backache awareness week starts 5th October

Self-reported fatigue predicts myelodysplastic syndromes survival

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Combination of two targeted therapies increases survival in advanced melanoma

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Kessler Foundation study may simplify cognitive assessment for MS in clinical settings

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Endurance training affects how the brain and muscles communicate with each other

New report calls for greater focus to address quality of life issues in prostate cancer patients

Tolerability benefits with sunitinib schedule switch

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News